Availability and funding of clinical genomic sequencing globally

Kathryn A Phillips, Michael P Douglas, Sarah Wordsworth, James Buchanan, Deborah A Marshall

ABSTRACT

The emergence of next-generation genomic sequencing (NGS) tests for use in clinical care has generated widespread interest around the globe, but little is known about the availability and funding of these tests worldwide. We examined NGS availability across world regions and countries, with a particular focus on availability of three key NGS tests—Whole-Exome Sequencing or Whole-Genome Sequencing for diagnosis of suspected genetic diseases such as intellectual disability disorders or rare diseases, non-invasive prenatal testing for common genetic abnormalities in fetuses and tumor sequencing for therapy selection and monitoring of cancer treatment. We found that these NGS tests are available or becoming available in every major region of the world. This includes both high-income countries with robust genomic programmes such as the USA and the UK, and growing availability in countries with upper-middle-income economies. We used exploratory case studies across three diverse health care systems (publicly funded/national (UK), publicly funded/provincial (Canada) and mixed private/public system (USA)) to illustrate the funding challenges and approaches used to address those challenges that might be adopted by other countries. We conclude by assessing what type of data and initiatives will be needed to better track and understand the use of NGS around the world as such testing continues to expand.

INTRODUCTION

The human genome was mapped 11 years ago, and since that time there has been a rapid growth in the number and scope of genetic tests. Historically, genetic testing was used for a limited set of diseases such as Down syndrome and sickle cell anaemia. However, tools such as ‘next-generation genomic sequencing’ (NGS) have emerged that can measure multiple genes and even the whole genome quickly and at a much lower cost. NGS is a broad term for a technology that measures genetic variation that is either present at birth or that emerges later in life. The emergence of NGS has generated widespread interest around the globe, with growth being driven by the need for better tools to predict, diagnose, treat and monitor disease in conjunction with increasingly efficient sequencing technologies.

NGS is used for a range of clinical applications:

► Risk assessment and disease screening, for example, germline cancer risk testing for Hereditary Breast and Ovarian Cancer or Lynch Syndrome

► Reproductive health decision making, for example, non-invasive prenatal testing (NIPT) for fetal genetic abnormalities, carrier screening for recessive genetic disorders such as cystic fibrosis.

► Diagnosis of an existing condition, for example, whole-exome sequencing (WES) or whole-genome sequencing (WGS) for diagnosis of suspected genetic diseases (SGD) such as intellectual disability disorders or rare diseases

► Diagnosis of infectious diseases, for example, SARS-CoV-2.

► Prognosis for a diagnosed disease, for example, FLT3 (fms-like tyrosine kinase 3) in acute myeloid leukaemia.

► Prediction/monitoring of treatment response or adverse events, for example, tumour sequencing (TS) for therapy selection and monitoring of cancer treatment.
pharmacogenomics panels to target current drug selection.

Understanding what tests are available is a key component in the ‘translational continuum’ for genomic medicine as this moves from discovery (T1) to evaluation of validity and clinical utility (T2) to health practice (T3) and then to population health impact (T4). However, there has not been an assessment of either the current availability of NGS or the process for developing a robust evidence base. Published studies have focused on specific testing applications such as BRCA1/2 (breast cancer type 1 and breast cancer type 2) testing for hereditary breast and ovarian cancer within specific healthcare systems, global governance, standardisation and data sharing, and projected market trends. Our study encourages the expansion of data collection with respect to NGS testing. Additional data collection on global availability and funding of NGS tests would benefit patients, providers, researchers and policymakers, both in countries with established availability and those with emerging availability.

Our objective is to expand our prior work on this topic by describing the availability and funding of NGS globally (figure 1). We begin by describing the availability of three key uses of NGS (WES/WGS, NIPT and TS) across world regions and countries. We then use exploratory case studies across three diverse healthcare systems to examine funding for WES/WGS in the context of SGDs, and illustrate the challenges and potential solutions that may be applicable to other countries. WES and WGS are starting to be used to diagnose SGDs, but countries have different approaches to payer coverage and public funding (‘funding’) between countries and across areas (provinces/regions) within countries. This variation can lead to differences in an individual’s chance of disease diagnosis and potential treatments according to which country they live in and where in that country they reside. Understanding the differences in funding and the evolution of these differences may help inform future challenges and potential solutions for implementation of genomic technologies into practice. Our final section describes what type of data will be needed and where such data might be obtained, and we conclude with next steps.

**Figure 1** Study framework: focus on T3 translation, implementation, and case studies of funding. NIPT, non-invasive prenatal testing; SGD; suspected genetic diseases, TS, tumour sequencing, WES; whole-exome sequencing; WGS, whole-genome sequencing.

**Clinical Genomic Sequencing is Available Across World Regions and Many Countries**

WES/WGS, NIPT and/or TS are available in many countries in all major regions of the world (table 1). ‘Availability’ measures where tests are available for clinical (vs research) use; although availability does not always translate into utilisation, it suggests where NGS is moving into clinical care.

Although it is widely known that NGS tests are available in high-income countries with robust genomic programmes such as the USA and the UK, tests are also becoming available in a range of other countries. Many European countries other than the UK have increasing availability of these tests and countries such as Australia have robust implementation. Availability is also increasing in countries with upper-middle-income economies. Although there are limited English language, peer-reviewed publications that describe implementation in Asia, the available studies illustrate the growth of genomic medicine (in general) and NGS (specifically). For example, Chong et al describe the landscape of genomic medicine adoption and implementation in four southeast Asian countries: Indonesia, Malaysia, Singapore and Thailand, noting that all four countries have
made progress but that there is significant heterogeneity across countries in clinical implementation.\(^9\) Another upper-middle-income country that illustrates the slow but significant growth of NGS is South Africa, where genetic testing services have been established.\(^{10}\) However, African countries face numerous challenges in increasing their research and clinical NGS capabilities.\(^{11}\)

**EXPLORATORY CASE STUDIES OF THREE COUNTRIES WITH VARYING FUNDING OF WHOLE-EXOME/GENOME-SEQUENCING FOR SGD**

Our case studies, based on published and unpublished literature as well as discussions with key experts in each country, are illustrative of three types of funding systems: 1. Publicly funded/national system: UK, which is one of a few countries with national, government-based funding for NGS (others include Belgium, Denmark, the Netherlands and Australia). 2. Publicly funded/provincial system: Canada, for which public funding of tests is provided at the provincial level after approval based on meeting specific criteria. 3. Mixed private/public system: USA, which has variable private and public insurer coverage.

Summaries of these case studies are in table 2.

**UK**

In the UK, coverage and funding for most genomic tests, including WES/WGS for SGD, is generally provided at the national level within the National Health Service (NHS). Private ordering and funding for WES/WGS is very limited.

A key driver for increased coverage of SGD testing in recent years has been the Genomics England 100000 Genomes Project. The project ran from 2013 to 2018 and sequenced 100000 genomes from around 85000 individuals, using WGS. All the participants were NHS patients affected by a SGD or cancer, recruited via one of 13 NHS Genomic Medicine Centres following referrals from physicians. The UK Department of Health considered the project to be a success due to its completion (demonstrating ability to test at scale) and because, especially for SGD, more diagnoses were made (greater diagnostic yield) than had been via non-WGS technologies. As WGS prices fell during the Project, WGS became a more affordable option if undertaken at large scale rather than in small testing laboratories. Increasing genomic sequencing also became a priority for the UK Life Sciences government agenda so there was significant government will and backing to see its use increased.

To build on this impetus, the Department of Health then set up a new national Genomic Medicine Service (GMS), which aims to take what had been achieved during the 100000 Genomes Project and make WGS for certain conditions part of a ‘normal’ mainstreamed genomic testing offering. The GMS will include WGS, WES and some panels, which will be the first time that WGS has been used in routine NHS care rather than within research projects. A key aim of the national genomic testing service is to reduce testing inequality and ensure that patients with similar conditions receive the same tests, regardless of where they live. The GMS includes a national genomic laboratory network made up of seven genomic laboratory hubs, a National Genomic Test Directory that specifies which suspected rare diseases should have first-line genomic tests, and an integrated clinical service. This test directory also specifies when a panel, WES or WGS should be used.\(^{12}\)

---

### Table 1: Availability of clinical genomic sequencing tests globally: whole-exome sequencing, non-invasive prenatal testing and tumour sequencing

<table>
<thead>
<tr>
<th>Test</th>
<th>North America</th>
<th>Central/ South America</th>
<th>Europe</th>
<th>Middle east</th>
<th>Asia/Oceania</th>
<th>Other countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole-exome sequencing</td>
<td>USA, Canada, Mexico</td>
<td>Brazil, Argentina, Colombia, Peru</td>
<td>UK, Germany Belgium, Denmark, Netherlands, Sweden, Italy, Spain, Ireland, Estonia, Finland, France</td>
<td>Saudi Arabia, Qatar, Turkey, Israel</td>
<td>Australia, China</td>
<td>South Africa</td>
</tr>
<tr>
<td>Non-invasive prenatal testing</td>
<td>USA, Canada, Mexico</td>
<td>Brazil, Argentina, Colombia, Peru</td>
<td>UK, France, Belgium, Denmark, Netherlands, Switzerland, Czech Republic, Sweden, Germany, Italy, Spain, Ireland</td>
<td>Saudi Arabia, Qatar, Turkey, Israel</td>
<td>Australia, China, Japan, South Korea, Taiwan</td>
<td>South Africa</td>
</tr>
<tr>
<td>Tumour sequencing</td>
<td>USA, Canada, Mexico</td>
<td>Brazil, Argentina, Chile, Colombia, Venezuela, Peru</td>
<td>UK, Belgium, Czech Republic, Netherlands, Sweden, Norway, France, Germany, Spain, Italy, Estonia, Finland, Ireland</td>
<td>Saudi Arabia, Qatar, Turkey, Israel</td>
<td>Australia, China, Japan, South Korea, Taiwan</td>
<td>South Africa, Egypt</td>
</tr>
</tbody>
</table>

Availability is based on the best available information obtained using a range of sources, including the grey literature and interviews with experts (personal communications, Veronique Forest, Marius Van Den Berg, 10/20/20).\(^{20}\) However, this table is illustrative and thus may not include all relevant countries. Also, we could not assess the availability of whole genome (vs exome) independently but many countries have both tests available.
The GMS, thus, reflects one solution that other countries could consider—centralisation and mainstreaming NGS test practices and policies. However, one of the main challenges of transitioning WGS into routine care in this way is the complexity of establishing the infrastructure to deliver a cutting-edge service with equitable provision nationally. One of the key issues to address is ensuring that there is capacity in the entire testing pipeline, from clinical referral for a test, through testing, bioinformatics analysis, interpreting results and then reporting the results back to patients. Delivering this at a national level requires significant organisation and coordination, which was achievable in the 100 000 Genomes Project, but has proven more challenging at very large scale.

**CANADA**

Clinical diagnostic WGS is not reimbursed in any provincial jurisdiction, while WES funding is provided in some but not all provinces. WES funding emerged from the use of other panels; panels for cancer and cardiovascular testing specifically have been in place for at least a decade because of their use in obtaining a diagnosis.

The need to control expenditures has contributed to a centralised system and review process for approving genetic testing. Provinces are similar in that they all have an application and approval process for WES; approved tests are mostly sent out of province, and tests are predominantly requested by medical geneticists. In general, the criteria for WES approval are: (1) it is deemed medically necessary by a qualified health professional; (2) no other alternative exists and (3) the results of the genetic test have an impact on clinical decision making. Provinces differ in the specific requirements, the steps in the process and the organisational body that approves the request.

One of the key challenges with expanding the use of WES/WGS further is the lack of infrastructure to deliver timely clinical exomes. Consequently, most WES testing is sent out of country. There are multiple layers of decision-making and a substantial amount of paperwork required to request testing. Since most requests are ultimately approved, the review process does not significantly reduce volume of testing but the time lag for approval (2–6 months in some provinces) can delay access to testing and appropriate follow-up. In some cases, patients are offered testing via private insurance or self-pay to reduce the time to testing and receipt of test results. Although this approach may reduce the current unmet need for WES/WGS, it remains controversial due to equity concerns (based on geographic location and the existence of financial for some patients).

Going forward, efforts are required to build appropriate infrastructure to undertake testing within provinces and for clinical applications in a timely way that is equitable to all patients. One approach to addressing infrastructure and equity concerns—which may be applicable to other countries—is the provincial Genomic Applications Partnership Programme (GAPP), which is aimed at translation and implementation of genomics into routine clinical practice. The platform being used—"All for One"—engages a wide array of stakeholders including institutions, regulators, and members of the rare disease clinical research community to work collaboratively to determine policy, governance, areas of

<table>
<thead>
<tr>
<th>Themes</th>
<th>UK</th>
<th>Canada</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current funding</td>
<td>▶ Funding provided at national level for WES and WGS w/in National Health Service</td>
<td>▶ WES funding varies by province and generally requires preapproval</td>
<td>▶ Funding varies by payer and test type/clinical scenario</td>
</tr>
<tr>
<td>Key factors influencing funding</td>
<td>▶ 100 000 Genomes Project provided evidence of increased diagnostic yield and reduced costs</td>
<td>▶ WES emerged from funding of multigene panels for other conditions</td>
<td>▶ Evidence of clinical utility, particularly for rapid testing in the NICU</td>
</tr>
<tr>
<td>Solutions for challenges</td>
<td>▶ Mainstreaming and coordinating testing through nationalised labs, test directory and clinical services</td>
<td>▶ Mainstreaming and centralising testing through development of infrastructures and clinical workflows to enable in-province test processing</td>
<td>▶ Use of inclusionary, consensus-building approach with stakeholders</td>
</tr>
<tr>
<td></td>
<td>▶ Developing consistent policies for patients with the same conditions</td>
<td>▶ Developing infrastructure for timely testing to enhance equitable access</td>
<td>▶ Focus on developing narrowly defined coverage policies that are not only medically appropriate but also feasible to implement</td>
</tr>
</tbody>
</table>

WES, whole-exome sequencing; WGS, whole-genome sequencing.
need and an ethical and legal framework. Although this platform is being developed within the context of rare diseases, it also has future applications as a model for other initiatives. The GAPP programmes are funded through Genome Canada and the respective provincial Genome agency in each province in partnership with a receptor organisation (such as the provincial laboratory and health services) and academic organisations. For example, in Alberta, the Translational Implementation of Genomics for Rare Diseases (TIGeR) GAPP programme was approved in 2020. TIGeR aims to address the lack of clinical sequencing infrastructure to deliver timely clinical exomes by optimising clinical workflows, building clinical genomics capacity within the province and driving the implementation of clinical genome wide sequencing and integrating genomic data into clinical practice in Alberta.

USA

There has been increased payer coverage of WES/WGS recently, but this varies by payer and is not universal. Currently, over half of insured individuals (private or public) have coverage for WES and/or WGS (63%).

This compares to the situation in 2015, when our study did not find any positive coverage policies among the five largest US private payers and few payers even had policies. Among individuals with private insurance, 71% have coverage for WES/WGS while among individuals with Medicaid insurance, only 39% have coverage. There are 27 state Medicaid programmes (as well as the District of Columbia) that do not provide any WES/WGS coverage. However, fewer insured individuals have coverage for WGS in addition to WES; only 8% of individuals with private insurance have coverage for both WES and WGS.

We previously examined why private payers may be increasing their coverage of WES/WGS and found that a key factor was that many payers were adopting an expanded view of its clinical utility. Payers stated that they were willing to provide coverage because they saw merit in using available interventions or ending the diagnostic odyssey—factors that previously had been insufficient to justify coverage, for example, half agreed that clinical utility extended beyond its impact on clinical outcomes and management to include ending the diagnostic odyssey, informational utility (directing family to disease-specific support, education and research) and family utility for reproductive decision making.

Another factor that has led to increased funding is acceptance of coverage for rapid WES/WGS in neonatal or paediatric intensive care units. Over half of insured individuals with coverage for both WES and WGS only have coverage in these settings. Coverage for rapid testing in the neonatal intensive care unit (NICU) has emerged because several studies have found evidence of improved outcomes including time to diagnosis, diagnostic yield, and changes to patient management over non-rapid testing. Of note is a recent study examining the impact of expanding Medicaid coverage for rapid WGS in the NICU in California. ‘Project Baby Bear’ found that rapid WGS ‘improves clinical outcomes, improves the experience of care for families and clinicians, and reduces net healthcare expenditures’ and recommended that rapid WGS be covered by Medicaid. It is unknown whether the outcomes of this study have changed Medicaid policies in California or other states or had a spillover effect on private payer policies, but it does provide an example of how even ‘safety net’ programmes can be innovative in developing the evidence to support changes in implementation and coverage policies.

The USA does not have a government organisation tasked with developing consistent policies and funding, hence other organisations have emerged to fill this gap—a situation that other countries without a national health system may face. One example is the Patient-Centred Laboratory Utilisation Guidance Services programme (PLUGS), which is a non-profit laboratory stewardship collaboration within Seattle Children’s Hospital Department of Laboratories. Their mission is to improve laboratory test ordering, retrieval, interpretation and reimbursement.

PLUGS uses a two-pronged approach to develop consistent and medically appropriate policies and funding that may be applicable to other countries:

1. An inclusionary approach that obtains perspectives from providers, labs and payers to seek consensus (they also solicit patient/parent input and share their results with patients/parents).

2. A focus on creating initial policies with narrow inclusion criteria rather than attempting to broadly cover tests, which then provides coverage for many of the sickest patients and creates a pathway for eventual expansion of criteria over time as clinically appropriate.

In 2016, PLUGS developed a consensus WES policy that was subsequently adopted and implemented by a national private payer, a lab benefit management company (that develops draft coverage policies for payers), and a state Medicaid plan among others. More recently, PLUGS created a WGS policy with criteria limited to the rapid inpatient setting based on clinical utility evidence in this patient population and knowledge of payer readiness to adopt coverage for this novel test.

DATA NEEDED FOR IMPLEMENTATION STUDIES AND POTENTIAL SOURCES

As noted previously, few studies have been published that empirically examine NGS implementation across countries. We, therefore, used grey literature and expert interviews to identify data gaps and possible data sources for three key implementation factors: availability, utilisation and funding. Table 3 shows that for each of these factors there are wide data gaps,
particularly outside the USA and Western Europe. There is some limited data on availability and utilisation of specific tests in targeted locations and for government-funded testing programmes. We note that a diverse range of data sources will be needed to obtain needed data, including grey literature and data from administrative and/or clinical databases.

**CONCLUSION**

We found that NGS tests are available in many countries across the globe and that many payers and health systems are funding NGS tests in at least some clinical scenarios. However, there are limited data, and thus, it is difficult to assess whether and how implementation is successful. Surprisingly few publications have addressed NGS global implementation especially in upper-middle-income countries, and thus, creative approaches are needed to identify and assess the required evidence. More data would be helpful to patients, providers, researchers and policy-makers. For example, one study found that the vast majority of studies are done on discovery (T1 in the translational continuum), demonstrating a need to increase research efforts in this area to implement promising genomic interventions into practice.27

We also found that some countries are implementing new approaches to improve implementation of NGS tests. By sharing experiences, lessons learnt can be leveraged and applied more broadly. Each country will have its own culture and constraints, but our case studies illustrated key leverage points. A key recommendation that emerges from the case studies is the need for coordinated, standardised, systematic testing infrastructure as well as stakeholder engagement in order to develop consistent, efficient and equitable practices and policies.

---

**Table 3** Data needed on implementation, data gaps and possible data sources

<table>
<thead>
<tr>
<th>Implementation factors</th>
<th>Data gaps (based on publicly available, accessible data sources)</th>
<th>Possible data sources with illustrative examples</th>
</tr>
</thead>
</table>
| Availability of NGS tests for clinical use | ► No source describes availability worldwide or across clinical applications  
► Limited and/or outdated information on many countries, particularly outside of North America and Western Europe | Published journal articles  
For example, Article from global collaborative that focuses on enabling the implementation of genomic medicine  
Grey literature*  
For example, Online news source such as GenomeWeb that reports on genomic test availability and utilisation  
Administrative and clinical data†  
For example, Registries such as the US National Institutes of Health (NIH) Genetic Testing Registry that consists of voluntary submissions by laboratories of their available tests |
| Utilisation (# tests ordered) | ► No source describes utilisation worldwide or across clinical applications  
► Limited data other than for US populations and in specific health plans or centres | Published journal articles  
For example, Article that describes US genetic test availability and spending based on claims data  
Grey literature*  
For example, Market reports such as investor analyses of NGS Market by product type  
Administrative and clinical data†  
For example, white papers such as Personalised Medicine Coalition’s report that used data integrated from claims, census and proprietary databases |
| Funding | ► No source describes funding worldwide or across clinical applications  
► Some data available for government-funded programmes and US private payer or Medicare coverage  
► Limited data on many countries, regional coverage and Medicaid coverage (USA) | Published journal articles  
For example, Article that reviewed coverage policies for ctDNA (liquid biopsy) tests  
Grey literature*  
For example, Advocacy group website such as Coalition for Access to Prenatal Screening  
Administrative and clinical data†  
For example, Proprietary and academic databases such as those developed by TRANSPERS and Canary Insights |

*Includes white papers, health system reports, market analyses, regulatory filings, company websites, news reports, national/international consortia websites.
†Includes electronic health records, claims data, fee schedules, industry databases, registries.
NGS, next-generation genomic sequencing.
We examined whether and how tests are being used in clinical care, but we did not examine another topic—‘implementation science’—the application of methods that promote uptake of research findings into practice. It has been noted by influential organisations that more emphasis needs to be placed on using such methods to define and measure successful implementation, identify efficient approaches, and increase study rigour.28 29 We also did not examine the clinical utility of tests—how tests improve patient outcomes—although we must consider not only what tests are implemented but whether they are appropriately implemented and provide value to patients and populations.

We acknowledge that we may have missed relevant studies or misclassified some countries as having test availability, given the lack of data and inconsistencies in definitions and measurements. Also, we note that many other factors determine whether NGS will be implemented into routine clinical care including patient and provider preferences and decision making, regulatory actions, infrastructure development and dissemination of information.5

In conclusion, the emergence of genomic sequencing tests for use in clinical care has generated widespread interest around the globe, but more information is required on how these tests are being used in clinical care particularly in upper-middle-income countries that are implementing NGS but where there have been few published studies. Key recommendations for advancing NGS are the development of coordinated, standardised, systematic testing infrastructure and stakeholder engagement.

Twitter Kathryn A Phillips @KathrynP_phd

Acknowledgements The authors gratefully acknowledge Dean Regier PhD, University of British Columbia for his contribution to the conceptualisation of the study in conjunction with the Global Economics and Evaluation of Clinical Genomics Sequencing (GEECS) Working Group. The authors also acknowledge the clinical and paying customers with whom we spoke to inform the case studies. Written permission has been obtained.

Contributors Substantial contributions to the conception or design of the work: all. Acquisition, analysis or interpretation of data: KAP and MPD. Drafting the work: KAP. Revising the work critically for important intellectual content: all. Final approval of the version published: all. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all.

Funding This study was funded by grants from the National Cancer Institutes (R01 CA221870) and National Human Genome Research Institute (U01 HG009599) and consulting contracts to KAP and MPD. DAM is supported by the Arthur J.E. Child Chair in Rheumatology, SW and JB are partly funded by the Oxford National Institute for Health Research Biomedical Research Centre.

Competing interests KAP receives consulting income from Illumina. Disclosures have been reviewed by the University of California San Francisco. MPD receives consulting income from Illumina. DAM, JB and SW have received travel expense reimbursement from Illumina to attend meetings.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The data that support the findings of this study are available from the corresponding author, KAP, upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Kathryn A Phillips http://orcid.org/0000-0003-0822-4968

REFERENCES


8 Phillips KA, Douglas MP, Marshall DA. Expanding use of clinical genome sequencing and the need for more data on implementation. JAMA 2020;324:2029.


